1. Disease modification and progression in pre-chronic obstructive pulmonary disease: an official American Thoracic Society workshop report.

Referencia Vancouver:
Putcha N, Bhatt SP, Bon J, Christenson SA, Han MK, Krishnan JA, et al. Disease modification and progression in pre-chronic obstructive pulmonary disease: an official American Thoracic Society workshop report. Ann Am Thorac Soc. 2026;23(5):667-688. doi:10.1093/annalsats/aaoag034. PMID:41671101.
Comentario:
Informe ATS sobre pre-EPOC y modificación de la enfermedad.

2. Development and validation of PRECISE-X model: predicting first severe exacerbation in COPD.

Referencia Vancouver:
Sadatsafavi M, Miravitlles M, Quint JK, et al. Development and validation of PRECISE-X model: predicting first severe exacerbation in COPD. Thorax. 2026;81(6):541-547. doi:10.1136/thorax-2025-223770. PMID:41476013.
Comentario:
Modelo predictivo de primera exacerbación grave.

3. Home-based rehabilitation with health coaching for rural patients living with COPD.

Referencia Vancouver:
Midthun WR, Beenken MJ, Benzo RP. Home-based rehabilitation with health coaching for rural patients living with COPD. Chest. Published online 2026. doi:10.1016/j.chest.2026.05.042. PMID:42270036.
Comentario:
Rehabilitación domiciliaria en áreas rurales.

4. Phenotyping asthma and/or chronic obstructive pulmonary disease using 129Xe MRI and comprehensive physiologic testing.

Referencia Vancouver:
Marshall H, Smith LJ, Biancardi A, et al. Phenotyping asthma and/or chronic obstructive pulmonary disease using 129Xe MRI and comprehensive physiologic testing. Am J Respir Crit Care Med. 2026;212(1):72-85. doi:10.1164/rccm.202501-0288OC. PMID:41072430.
Comentario:
Fenotipado funcional avanzado mediante RM con xenón.

5. Computed tomography total vessel count and vessel count percentages: associations with exercise capacity, symptoms and rapid FEV1 decline in COPD.

Referencia Vancouver:
Singh GV, Asghar H, Collins SE, et al. Computed tomography total vessel count and vessel count percentages: associations with exercise capacity, symptoms and rapid FEV1 decline in COPD. Eur Respir J. 2026;67(3):2500560. doi:10.1183/13993003.00560-2025. PMID:41360509.
Comentario:
Marcadores vasculares por TC y progresión.

6. Persistent homology analysis of longitudinal computed tomography fibrotic features in COPD.

Referencia Vancouver:
Shiraishi Y, Tanabe N, Kaji S, et al. Persistent homology analysis of longitudinal computed tomography fibrotic features in COPD. Eur Respir J. 2026;68(1):2501630. doi:10.1183/13993003.01630-2025. PMID:41748284.
Comentario:
Fibrosis cuantitativa y pronóstico.

7. Mucus plugs in chronic obstructive pulmonary disease are heterogeneous in size and shape and occur in relatively large airways.

Referencia Vancouver:
Farooqui ON, Elicker BM, Henry TS, et al. Mucus plugs in chronic obstructive pulmonary disease are heterogeneous in size and shape and occur in relatively large airways. Am J Respir Crit Care Med. 2026;212(2):268-276. doi:10.1093/ajrccm/aamaf138. PMID:41738094.
Comentario:
Caracterización de tapones mucosos.

8. A GOLD Science Committee perspective on exacerbations and cardiovascular risk in COPD.

Referencia Vancouver:
Singh D, et al. A GOLD Science Committee perspective on exacerbations and cardiovascular risk in COPD. Am J Respir Crit Care Med. Published online 2026. doi:10.1093/ajrccm/aamag231. PMID:42104206.
Comentario:
Documento de perspectiva GOLD.

9. Bisoprolol to prevent adverse cardiac events in COPD: PACE trial.

Referencia Vancouver:
Jenkins CR, Martin A, Chang CL, et al. Bisoprolol to prevent adverse cardiac events in COPD: PACE trial. Lancet Respir Med. 2026;14(3):203-214. doi:10.1016/S2213-2600(25)00390-X. PMID:41579873.
Comentario:
Ensayo sobre prevención cardiovascular.